SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Pretzel Therapeutics Receives UK Authorization to Advance PX578 Into Clinical Development

The authorization allows development of PX578 in patients with POLG-mediated primary mitochondrial disorders. The milestone follows U.S. FDA clearance of its investigational new drug application in August.

Related stories